2014 CMHC - Educational Grant Supporters

For more information regarding educational grant support opportunities for the Cardiometabolic Health Congress
please email info@cardiometabolichealth.org or call 877.571.4700.

The 2014 CMHC gratefully acknowledges the educational grant support provided by the following organizations:

Improving Awareness and Outcomes in Lipodystrophy Syndromes: Clinical Manifestations, Diagnosis, and Evolving Therapeutic Strategies
Supported by an educational grant from AstraZeneca

Optimizing Antihypertensive Therapies in High-Risk and Difficult-to-Treat Patients with Hypertension
Supported by an educational grant from Forest Laboratories, Inc.

New Frontiers in Obesity Management: Advances in Neurobiological Treatment Strategies
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc

Triglyceride and Mixed Dyslipidemia Management: The Changing Landscape of CV Risk Reduction
Supported by an educational grant from AstraZeneca

Obesity Management 2014: New Perspectives and Therapeutic Options for a Growing Problem
Supported by an educational grant from Novo Nordisk, Inc.

Overcoming Obstacles in Obesity Management: New Tools, Techniques, and Treatment Strategies
Supported by an educational grant from Eisai, Inc.

Closing the Gaps in the Continuum of Care for Patients with Acute Coronary Syndromes: Implications for Optimal Antiplatelet Use
Supported by an educational grant from AstraZeneca

Novel and Emerging Combinations to Achieve Glycemic Control and Reduce Cardiometabolic Risk: A Focus on Incretin-Based Therapy and SGLT2 Inhibitors
Supported by an educational grant from AstraZeneca

The Triglycerides Conundrum: Practical Clinical Guidance for Reducing Residual CV Risk
Supported by an educational grant from Amarin Pharma, Inc.

Innovations in GLP-1 Receptor Agonist Therapy: Individualized Treatment Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in Type 2 Diabetes Mellitus
Supported by an educational grant from Lilly USA, LLC

Individualizing Therapy in Patients with Stable Ischemic Heart Disease: Managing the Full Spectrum of Comorbidities and Cardiometabolic Risk Factors
Supported by an educational grant from Gilead Sciences, Inc.

The Wide Spectrum of Familial Hypercholesterolemia: Discovering Your Highest Risk Patients and Optimizing Treatment
Supported by educational grants from Aegerion Pharmaceuticals, Inc. and Genzyme, A SANOFI COMPANY

Integrated Management of the Complexities of Cardiometabolic Diseases: A Patient-Centric Team Approach
Supported by an educational grant from Merck & Co., Inc.

Confronting Racial and Ethnic Disparities in Cardiometabolic Disease
Supported in part by educational grants from Arbor Pharmaceuticals and Merck & Co.

New Targets and Treatments for LDL Lowering: Role of PCSK9 Inhibitors
Supported by an educational grant from Amgen

Evolving Strategies for LDL-Lowering: Novel Targets and Treatments For CVD Risk Reduction
Supported by an educational grant from Sanofi US and Regeneron Pharmaceuticals